Abstract: The masking material includes a penetrating portion according to a predetermined pattern. The masking material includes a mask portion and at least the mask portion contacting the substrate is made of an elastic material. The penetrating portion includes an expanded portion that is expanded outwardly from a portion contacting the substrate toward the electrolyte membrane in a thickness direction of the mask portion such that in a state where the mask portion is elastically deformed by a pressing force of the electrolyte membrane, a shape of a cross section of a formation space of the penetrating portion in which the metal film is to be formed becomes rectangular.

Abstract: The film forming apparatus includes a pressing mechanism that presses the mask structure by the electrolyte membrane with a fluid pressure of a plating solution. The mask structure includes a screen mask in which a penetrating portion corresponding to a predetermined pattern is formed, and a frame that supports a peripheral edge of the screen mask on a side adjacent to the substrate. In the frame, an inner covering portion made of an elastic material softer than a material of the frame is formed along an opening edge contacting the electrolyte membrane.

Abstract: The method includes: placing a substrate on a mount base; covering the substrate with the screen mask including a penetrating portion of a predetermined pattern; pressing the substrate by the electrolyte membrane with a fluid pressure of a plating solution contacting the electrolyte membrane via the screen mask; and applying a voltage between an anode contacting the plating solution and the substrate so as to allow metal ions contained in the plating solution to pass through the electrolyte membrane and form a metal film derived from the metal ions in the predetermined pattern on the substrate. The substrate includes an outer edge portion formed by an opposite surface facing the screen mask and a side surface. A cushion member is disposed along the outer edge portion before pressing the substrate.

Abstract: A mask structure includes a screen mask having a penetrating portion with a predetermined pattern. The screen mask includes a mesh portion having an opening formed in a grid pattern, and a mask portion having the penetrating portion and being fixed to the mesh portion so as to face the substrate. The mask portion includes a core portion that retains the shape of the mask portion, and a seal portion made of an elastic material softer than the material of the core portion and contacting the substrate.

Abstract: A control method for an information processing apparatus capable of wirelessly communicating with a communication apparatus, includes: executing, based on a fact that a predetermined access point different from the information processing apparatus and different from the communication apparatus supports a network setup by a predetermined protocol, transmission control for transmitting, to the communication apparatus, a signal for causing the communication apparatus to start a predetermined operation for the network setup by the predetermined protocol; and executing processing for executing the network setup by the predetermined protocol in the information processing apparatus.

Abstract: A film formation apparatus includes an anode, a solid electrolyte membrane between the anode and a substrate, a power supply that applies voltage between the anode and the substrate as a cathode, and a liquid reservoir that holds the anode and the solid electrolyte membrane while separating them apart from each other, the liquid reservoir storing electrolyte solution including metal ions between the anode and the solid electrolyte membrane. The solid electrolyte membrane includes a central portion that comes in contact with the substrate and the electrolyte solution, and an outer edge portion outside the central portion. The apparatus includes a membrane tensioning mechanism to apply a tensile force to the central portion toward the outer edge portion while storing the heated electrolyte solution in the liquid reservoir, to elongate the central portion.

Abstract: Embodiments provide a coating material including (A) 100 parts by mass of an active-energy-ray-curable resin, (B) 5 to 200 parts by mass of aluminum oxide particles having an average particle diameter of 1 to 100 ?m, (C) 0.1 to 20 parts by mass of aluminum oxide microparticles having an average particle diameter of 1 to 100 nm, and (D) 0.1 to 40 parts by mass of a compound having at least two isocyanate groups per molecule, where the active-energy-ray-curable resin (A) includes (a1) 70 to 99% by mass of a polyfunctional (meth)acrylate and (a2) 30 to 1% by mass of an acrylamide compound having at least one hydroxyl group per molecule, and the sum total of the amount of the polyfunctional (meth)acrylate (a1) and the amount of the acrylamide compound (a2) having at least one hydroxyl group per molecule is 100% by mass.

Abstract: Embodiments provide a coating material containing: (A) 100 parts by mass of an acrylic curable resin; (B) 5-200 parts by mass of aluminum oxide particles having an average particle size of 1-100 ?m; (C) 0.1-20 parts by mass of aluminum oxide fine particles having an average particle size of 1-100 nm; and (D) 1-100 parts by mass of a compound having two or more isocyanate groups per molecule. In one embodiment, the acrylic curable resin (A) includes: (a1) a structural unit derived from a hydroxy group-containing (meth)acrylic acid ester; (a2) a structural unit derived from a vinyl aromatic compound; and (a3) a structural unit derived from a (meth)acrylic acid alkyl ester. In one embodiment, the acrylic curable resin (A) may contain, in addition to the structural units (a1) and (a2): (a3-1) a structural unit derived from methyl methacrylate; and (a3-2) a structural unit derived from an aliphatic (including alicyclic) alkyl ester having 4 or more carbon atoms of a (meth)acrylic acid.

Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.

Abstract: The present invention provides a method for treating or preventing a renal injury-related disease such as diabetic nephropathy comprising administering to a mammal a therapeutically effective amount of 2-({[7-hydroxy-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]carbonyl}amino)acetic acid or a pharmaceutically acceptable salt thereof, and a novel pharmaceutical use of the aforementioned compound such as a pharmaceutical composition for treating or preventing a renal injury-related disease and the like comprising the aforementioned compound or a pharmaceutically acceptable salt thereof.

Abstract: Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).

Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.

Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.

Abstract: Embodiments provide a coating material containing: (A) 100 parts by mass of an acrylic curable resin; (B) 5-200 parts by mass of aluminum oxide particles having an average particle size of 1-100 ?m; (C) 0.1-20 parts by mass of aluminum oxide fine particles having an average particle size of 1-100 nm; and (D) 1-100 parts by mass of a compound having two or more isocyanate groups per molecule. In one embodiment, the acrylic curable resin (A) includes: (a1) a structural unit derived from a hydroxy group-containing (meth)acrylic acid ester; (a2) a structural unit derived from a vinyl aromatic compound; and (a3) a structural unit derived from a (meth)acrylic acid alkyl ester. In one embodiment, the acrylic curable resin (A) may contain, in addition to the structural units (a1) and (a2): (a3-1) a structural unit derived from methyl methacrylate; and (a3-2) a structural unit derived from an aliphatic (including alicyclic) alkyl ester having 4 or more carbon atoms of a (meth)acrylic acid.

Abstract: Embodiments provide a coating material including (A) 100 parts by mass of an active-energy-ray-curable resin, (B) 5 to 200 parts by mass of aluminum oxide particles having an average particle diameter of 1 to 100 ?m, (C) 0.1 to 20 parts by mass of aluminum oxide microparticles having an average particle diameter of 1 to 100 nm, and (D) 0.1 to 40 parts by mass of a compound having at least two isocyanate groups per molecule, where the active-energy-ray-curable resin (A) includes (a1) 70 to 99% by mass of a polyfunctional (meth)acrylate and (a2) 30 to 1% by mass of an acrylamide compound having at least one hydroxyl group per molecule, and the sum total of the amount of the polyfunctional (meth)acrylate (a1) and the amount of the acrylamide compound (a2) having at least one hydroxyl group per molecule is 100% by mass.

Abstract: Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).

Abstract: Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).

Abstract: One embodiment is a cosmetic sheet having a transparent adhesive layer (A), a transparent resin film layer (B), a printed layer (C), and a resin film layer (D) in this order from the side adhered to a transparent substrate, where: the transparent resin film layer (B) as a whole has an embossed profile; the printed layer (C) contains a high-brightness pigment; the printed layer (C) as a whole has an embossed profile; and the resin film layer (D) has an embossed profile on the side facing the printed layer (C). Another embodiment is a cosmetic sheet which has a transparent resin layer (E) between the layers of (A) and (B), where this transparent resin layer (E) has an embossed profile on the side facing the transparent resin film layer (B). The adhesive layer (A) may contain prescribed amounts of an acrylic polymer (P) having a glass transition temperature between ?50° C. and ?25° C.

Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.

Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.